Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
At MWC's 4YFN showcase, AI startups are proving real-world impact beyond frontier models, with Ultralytics hitting 2.5 billion inferences, Biorce raising $52 million for clinical trials, and NeuralTrust securing EU backing to protect enterprise AI systems from cyber threats.
Isomorphic Labs unleashes IsoDDE, a groundbreaking AI drug-discovery engine that outperforms open-source rivals in predicting drug-protein interactions, but scientists are raising concerns as the powerful DeepMind spin-off keeps its technology fully proprietary, blocking the broader research community from replicating or building on its breakthroughs.
NVIDIA launches a $1 billion AI drug discovery lab with pharmaceutical giant Lilly and expands its BioNeMo platform, partnering with major life sciences companies to automate scientific discovery through AI models that predict molecular structures and connect digital agents to robotic laboratory systems.
NVIDIA and Eli Lilly unveil a groundbreaking $1 billion AI co-innovation lab that promises to revolutionize drug discovery by creating a continuous learning system connecting physical laboratories with computational AI for round-the-clock experimentation and pharmaceutical development.
Utah becomes the first state to legally allow AI to autonomously renew prescriptions for chronic conditions through a partnership with platform Doctronic, while federal legislation proposes expanding AI prescribing authority nationwide.
Excelsior Sciences secures $95 million to revolutionize drug discovery by replacing human chemists with AI-powered robots that break down FDA-approved molecules into 'smart bloccs' and reassemble them into new pharmaceutical compounds, promising faster and cheaper development while reshoring manufacturing to the US.
Valthos emerges from stealth with $30 million from OpenAI and top venture firms to build AI systems that detect biological threats in real-time, promising to slash response times from months to hours using frontier artificial intelligence technology.
Anthropic launches Claude for Life Sciences, its first specialized AI platform for the sector, promising to slash research tasks from days to minutes by integrating with scientific tools like PubMed and Benchling to accelerate discovery from literature reviews to regulatory submissions.
Cortical Labs launches CL1, the world's first commercial biological computer that harnesses 800,000 lab-grown human neurons to process data with submillisecond response times, offering a $35,000 energy-efficient alternative to traditional computing for pharmaceutical, financial, and AI research applications.